AR124505A2 - COMPOSITIONS RELATED TO A MUTANT CLOSTRIDIUM DIFFICILE TOXIN AND THEIR METHODS - Google Patents
COMPOSITIONS RELATED TO A MUTANT CLOSTRIDIUM DIFFICILE TOXIN AND THEIR METHODSInfo
- Publication number
- AR124505A2 AR124505A2 ARP210103660A ARP210103660A AR124505A2 AR 124505 A2 AR124505 A2 AR 124505A2 AR P210103660 A ARP210103660 A AR P210103660A AR P210103660 A ARP210103660 A AR P210103660A AR 124505 A2 AR124505 A2 AR 124505A2
- Authority
- AR
- Argentina
- Prior art keywords
- difficile toxin
- mutant
- clostridium difficile
- methods
- relates
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 239000003053 toxin Substances 0.000 title abstract 4
- 231100000765 toxin Toxicity 0.000 title abstract 4
- 241000193163 Clostridioides difficile Species 0.000 title abstract 3
- 108700012359 toxins Proteins 0.000 abstract 3
- 230000002163 immunogen Effects 0.000 abstract 2
- 230000035772 mutation Effects 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 108700022831 Clostridium difficile toxB Proteins 0.000 abstract 1
- 102000005927 Cysteine Proteases Human genes 0.000 abstract 1
- 108010005843 Cysteine Proteases Proteins 0.000 abstract 1
- 102000051366 Glycosyltransferases Human genes 0.000 abstract 1
- 108700023372 Glycosyltransferases Proteins 0.000 abstract 1
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 101710084578 Short neurotoxin 1 Proteins 0.000 abstract 1
- 101710182532 Toxin a Proteins 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 235000001014 amino acid Nutrition 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 abstract 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 abstract 1
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
En un aspecto, la invención se refiere a una composición inmunogénica que incluye una toxina A de Clostridium difficile mutante y/o una toxina B de Clostridium difficile mutante. Cada toxina mutante incluye un dominio de glucosiltransferasa que tiene al menos una mutación y un dominio de cisteína proteasa que tiene al menos una mutación, con respecto a la correspondiente toxina de C. difficile tipo salvaje. Las toxinas mutantes también pueden incluir al menos un aminoácido que está entrecruzado químicamente. En otro aspecto, la invención se refiere a anticuerpos o fragmentos de unión a este que se unen a dichas composiciones inmunogénicas. En un aspecto adicional, la invención se refiere a secuencias de nucleótidos aisladas que codifican alguna de los precedentes y los métodos de cualquiera de las composiciones precedentes. Reivindicación 1: Un polipéptido aislado, caracterizado porque comprende la secuencia de aminoácidos de SEQ ID Nº 6, donde el residuo metionina en la posición 1 de SEQ ID Nº 6 no está presente, donde un residuo lisina del polipéptido está entrecruzado a un grupo b-alanina.In one aspect, the invention relates to an immunogenic composition including a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. Each mutant toxin includes a glycosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins can also include at least one amino acid that is chemically cross-linked. In another aspect, the invention relates to antibodies or binding fragments thereto that bind to said immunogenic compositions. In a further aspect, the invention relates to isolated nucleotide sequences encoding any of the foregoing and methods of any of the foregoing compositions. Claim 1: An isolated polypeptide, characterized in that it comprises the amino acid sequence of SEQ ID No. 6, where the methionine residue at position 1 of SEQ ID No. 6 is not present, where a lysine residue of the polypeptide is crosslinked to a b-group to the girl.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161478474P | 2011-04-22 | 2011-04-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR124505A2 true AR124505A2 (en) | 2023-04-05 |
Family
ID=86380134
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210103660A AR124505A2 (en) | 2011-04-22 | 2021-12-23 | COMPOSITIONS RELATED TO A MUTANT CLOSTRIDIUM DIFFICILE TOXIN AND THEIR METHODS |
Country Status (1)
| Country | Link |
|---|---|
| AR (1) | AR124505A2 (en) |
-
2021
- 2021-12-23 AR ARP210103660A patent/AR124505A2/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR086199A1 (en) | COMPOSITIONS RELATED TO A MUTANT DIFFICILE CLOSTRIDIUM TOXIN AND ITS METHODS | |
| MX2019013075A (en) | COMPOSITIONS AND METHODS RELATED TO A CLOSTRIDIUM DIFFICILE MUTANT TOXIN. | |
| MX2024002398A (en) | Gdf15 fusion proteins and uses thereof. | |
| BR112016014810A2 (en) | FCRN ANTAGONISTS AND METHODS OF USE | |
| MX387336B (en) | CLOSTRIDIUM HISTOLYTICUM ENZYMES AND METHODS FOR THEIR USE. | |
| EA201270517A1 (en) | МИКОБАКТЕРИАЛЬНЫЕ ВАКЦИНЫ | |
| CY1119916T1 (en) | IMMUNE COMPOSITION | |
| AR094275A1 (en) | IMMUNOGENIC COMPOSITION INCLUDING THE CDTb PROTEIN OF CLOSTRIDIUM DIFFICILE | |
| EA201100070A1 (en) | RV2386C TUBERCULOSIC PROTEIN, COMPOSITIONS AND THEIR APPLICATIONS | |
| CY1124110T1 (en) | MUTANT FACTOR COMPOSITIONS AND METHODS VIII | |
| PE20191248A1 (en) | NEW PEPTIDES AND NEW PEPTIDE COMBINATIONS FOR USE IN IMMUNOTHERAPY AGAINST OVARIAN CANCER AND OTHER TYPES OF CANCER | |
| EA201100072A1 (en) | NEW COMPOSITIONS AND METHODS | |
| PE20171652A1 (en) | NEW SPECIFIC PROTEINS FOR PIOVERDIN AND PIOQUELIN | |
| AR102950A1 (en) | LIPASE AND POLINUCLEOTIDE VARIANTS CODING THEM | |
| BR112015013004A2 (en) | isolated nucleic acid molecule, composition, vaccine, methods of treating an individual and preventing a tumor, protein, and peptide | |
| BR112016015678A2 (en) | POLYPEPTIDE CONTAINING MUTANTED FRAGMENTS OF OSPA, NUCLEIC ACID, VECTOR, HOST CELL, PROCESS FOR THEIR PRODUCTION, PHARMACEUTICAL COMPOSITION, AND ITS USE | |
| SA518400443B1 (en) | Method for purification and activation of botulinum neurotoxin | |
| BR112016011091A2 (en) | modified endolysin sequence kz144 | |
| EA201891141A1 (en) | NEW ANTIANGIOGENIC FUSED POLYPEPTIDES | |
| BR112016011095A2 (en) | MODIFIED ENDOLISIN EL188 SEQUENCE | |
| MX365560B (en) | Cyaa-based chimeric proteins comprising a heterologous polypeptide and their uses in the induction of immune responses. | |
| AR124505A2 (en) | COMPOSITIONS RELATED TO A MUTANT CLOSTRIDIUM DIFFICILE TOXIN AND THEIR METHODS | |
| EA201591861A1 (en) | RECOMBINANT TOXIN PASTEURELLA MULTOCIDA AND ITS APPLICATION | |
| MX374380B (en) | IMMUNOGENIC COMPOSITION OF CLOSTRIDIUM DIFFICILE. |